Parkinson’s Disease Treatment

Parkinson’s disease is a progressive neurodegenerative disorder affecting the central nervous system. It advances slowly and is characterized by distinctive motor deficits resulting from the reduction of the neurotransmitter dopamine. The cause of dopamine depletion remains unknown, but it is associated with the demise of a specific group of cells located deep within the brain in an area known as the substantia nigra.

Parkinson’s disease is characterized by distinctive motor deficits, including a slowing of physical movement, muscle rigidity, involuntary resting tremor, postural instability, and gait disturbances. The underlying cause of the disease lies in the abnormal functioning of the basal ganglia, deep structures within the brain responsible for the automatic aspects of movement, executed precisely and without conscious control.

Typically, basal ganglia neurons release the neurotransmitter dopamine, crucial for motor control. In Parkinson’s disease, there is a compromise in either dopamine release or dopamine receptors. As the disease progresses, motor disturbances extend to speech and swallowing control. Speech becomes slow and soft, and in severe cases, it may reduce to little more than a whisper due to difficulties in forcing air through the windpipes, necessary for raising one’s voice.

Approximately 1-2% of the population is affected by Parkinson’s disease, with an estimated 1 million patients in the U.S. alone. In Israel, where there is no centralized registry of Parkinson patients, estimates suggest a population of 60,000 to 100,000 patients based on the prevalence of the disease in the general population. Onset typically occurs around the age of 57-58, and the prevalence increases with age.

The exact causes of Parkinson’s disease remain unclear, although genetic factors have been proposed. In a subset of patients, exposure to heavy metals like manganese has been implicated. Impairment of the liver’s detoxification ability may also play a role, as individuals with compromised detoxification abilities face an increased risk of harm from neurotoxins. Prolonged exposure to such neurotoxins in these individuals can lead to damage that eventually manifests as clinical disease. Other risk factors include age, as the average onset age is 57, and a family history of the disease.

Conventional Treatments

Parkinson’s disease is characterized by distinctive motor deficits, including a slowing of physical movement, muscle rigidity, involuntary resting tremor, postural instability, and gait disturbances. The underlying cause of the disease lies in the abnormal functioning of the basal ganglia, deep structures within the brain responsible for the automatic aspects of movement, executed precisely and without conscious control.

Typically, basal ganglia neurons release the neurotransmitter dopamine, crucial for motor control. In Parkinson’s disease, there is a compromise in either dopamine release or dopamine receptors. As the disease progresses, motor disturbances extend to speech and swallowing control. Speech becomes slow and soft, and in severe cases, it may reduce to little more than a whisper due to difficulties in forcing air through the windpipes, necessary for raising one’s voice.

Approximately 1-2% of the population is affected by Parkinson’s disease, with an estimated 1 million patients in the U.S. alone. In Israel, where there is no centralized registry of Parkinson patients, estimates suggest a population of 60,000 to 100,000 patients based on the prevalence of the disease in the general population. Onset typically occurs around the age of 57-58, and the prevalence increases with age.

The exact causes of Parkinson’s disease remain unclear, although genetic factors have been proposed. In a subset of patients, exposure to heavy metals like manganese has been implicated. Impairment of the liver’s detoxification ability may also play a role, as individuals with compromised detoxification abilities face an increased risk of harm from neurotoxins. Prolonged exposure to such neurotoxins in these individuals can lead to damage that eventually manifests as clinical disease. Other risk factors include age, as the average onset age is 57, and a family history of the disease.

Get In touch

+1 (305) 828-9980

available from 10:00 – 19:00

Address 1840 W 49 ST STE 404 Hialeah, FL 33012

Email info@capotetms.com

Skip to content